News

As per the terms of the agreement, BASF will use Dyadic’s patented and proprietary C1 platform technology to develop, manufacture, distribute and sell industrial enzymes in certain fields

As per the extension agreement, Galapagos will fund and complete a Phase 2 program in Crohn’s disease, which is designed to facilitate rapid progression into Phase 3. AbbVie

Neucardin is a genetically engineered recombinant peptide fragment of neuregulin-1 that is used as a therapeutic drug to treat advanced chronic heart failure (CHF). As per the terms

DCVax-L mobilizes a cancer patient’s whole immune system to attack the full set of biomarker targets on the tumour. King’s College Hospital neuro-oncology lead and consultant neurosurgeon Dr.

Almac and the departments of Biochemical Engineering and Chemistry at UCL are set to complete the R&D work with high level input from professors John Ward and Helen

The safety and tolerability profile of single ascending doses of TTI-1612 will be assessed in the study. Stem Cell Therapeutics chief scientific officer Dr. Bob Uger said, "We

The new anti-bacterial agents will be based on a highly validated target family involved in bacterial cell wall biosynthesis. Evotec CEO Dr Werner Lanthaler said, "The lack of

The product is presently in the development stage for the treatment of chemotherapy-induced nausea and vomiting (CINV). As per the terms of the deal, Vifor Pharma will not

The power of cognitive computing capabilities, such as IBM’s Watson, will be exploited under the project. The project will leverage big data and analytics to deliver personalised care